Leslie Stolz

Consigliere Generale presso VERVE THERAPEUTICS, INC.

52 anni

Health Technology

Consumer Services

Profilo

Leslie Stolz is currently working as the Senior Vice President-Regulatory Affairs at Verve Therapeutics, Inc. Prior to this, Leslie worked as the Vice President-Regulatory Strategy at Syntimmune, Inc. Leslie holds a doctorate degree from Duke University and an undergraduate degree from Villanova University.

Posizioni attive di Leslie Stolz

Società	Posizione	Inizio
VERVE THERAPEUTICS, INC.	Consigliere Generale	01/06/2019

Tutte le posizioni attive di Leslie Stolz

Precedenti posizioni note di Leslie Stolz

Società	Posizione	Fine
Syntimmune, Inc. Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.	Corporate Officer/Principal	01/01/2018

Vedi nel dettaglio l'esperienza di Leslie Stolz

Formazione di Leslie Stolz

Duke University	Doctorate Degree
Villanova University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Leslie Stolz

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
VERVE THERAPEUTICS, INC.	Health Technology

Aziende private	1
Syntimmune, Inc. Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.	Health Technology